234 related articles for article (PubMed ID: 30262660)
1. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP; Rouce R; Gottschalk S; Torrano V; Carrum G; Wu MF; Hoq F; Grilley B; Marcogliese AM; Hanley PJ; Gee AP; Brenner MK; Rooney CM; Heslop HE; Bollard CM
Blood; 2018 Nov; 132(22):2351-2361. PubMed ID: 30262660
[TBL] [Abstract][Full Text] [Related]
2. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
3. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study.
Watanabe Y; Sasahara Y; Satoh M; Looi CY; Katayama S; Suzuki T; Suzuki N; Ouchi M; Horino S; Moriya K; Nanjyo Y; Onuma M; Kitazawa H; Irie M; Niizuma H; Uchiyama T; Rikiishi T; Kumaki S; Minegishi M; Wada T; Yachie A; Tsuchiya S; Kure S
Eur J Haematol; 2013 Sep; 91(3):242-248. PubMed ID: 23734904
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
6. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.
Moosmann A; Bigalke I; Tischer J; Schirrmann L; Kasten J; Tippmer S; Leeping M; Prevalsek D; Jaeger G; Ledderose G; Mautner J; Hammerschmidt W; Schendel DJ; Kolb HJ
Blood; 2010 Apr; 115(14):2960-70. PubMed ID: 20103780
[TBL] [Abstract][Full Text] [Related]
7. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
8. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
9. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
Cohen JI; Jaffe ES; Dale JK; Pittaluga S; Heslop HE; Rooney CM; Gottschalk S; Bollard CM; Rao VK; Marques A; Burbelo PD; Turk SP; Fulton R; Wayne AS; Little RF; Cairo MS; El-Mallawany NK; Fowler D; Sportes C; Bishop MR; Wilson W; Straus SE
Blood; 2011 Jun; 117(22):5835-49. PubMed ID: 21454450
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphoma of human immunodeficiency virus-negative Japanese.
Ohshima K; Suzumiya J; Tasiro K; Mukai Y; Tanaka T; Kato A; Kikuchi M
Am J Hematol; 1996 May; 52(1):21-8. PubMed ID: 8638607
[TBL] [Abstract][Full Text] [Related]
12. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
14. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
15. EBV-associated lymphoproliferative disease post-CAR-T cell therapy.
Zhang S; Zhou X; Zhang S; Wang N; Zhang T; Zhang D; Ao Q; Cao Y; Huang L
Front Med; 2024 Apr; 18(2):394-398. PubMed ID: 38329597
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas.
Jung CK; Lee KY; Kim Y; Han K; Shim SI; Kim BK; Kang CS
Pathol Int; 2001 May; 51(5):355-63. PubMed ID: 11422793
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
Finberg RW
Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
[TBL] [Abstract][Full Text] [Related]
20. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]